Gyre Therapeutics (NASDAQ:GYRE) and Hypermarcas (OTCMKTS:HYPMY) Head to Head Comparison

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) and Hypermarcas (OTCMKTS:HYPMY – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings for Gyre Therapeutics and Hypermarcas, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gyre Therapeutics 1 1 0 0 1.50
Hypermarcas 0 1 0 1 3.00

Profitability

This table compares Gyre Therapeutics and Hypermarcas’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gyre Therapeutics -14.80% -7.39% -5.74%
Hypermarcas 20.07% 12.58% 7.00%

Insider and Institutional Ownership

24.0% of Gyre Therapeutics shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Gyre Therapeutics and Hypermarcas”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gyre Therapeutics $116.59 million 4.43 $5.03 million ($0.20) -22.40
Hypermarcas $1.38 billion 2.01 $213.10 million $0.52 7.58

Hypermarcas has higher revenue and earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Hypermarcas, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Gyre Therapeutics has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500. Comparatively, Hypermarcas has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.

Summary

Hypermarcas beats Gyre Therapeutics on 9 of the 13 factors compared between the two stocks.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.

About Hypermarcas

(Get Free Report)

Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories. Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo QuĂ­mica and Mantecorp.

Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.